Capstone Therapeutics Corp banner

Capstone Therapeutics Corp
R&D

R&D · Jun 2019 report

R&D increased in the latest quarter

-$427k
+29%
-$1m
+0.2%
-$1.5m
-19.7% YoY

Quarterly R&D reached -$427k, down 32.6% year over year and up 29% sequentially; LTM R&D was -$1.5m, down 7.3% from the preceding LTM observation of -$1.4m.

Growth

Horizon Past Forecast Difference
Quarter N/A N/A
1 year N/A N/A
3-year CAGR N/A N/A
5-year CAGR N/A N/A
10-year CAGR N/A N/A

No analyst forecasts are available for R&D.

History

Statistic Value Reporting period
Average value -$4.7m Dec 2008 – Dec 2017
Median value -$2.7m Dec 2008 – Dec 2017
Highest value -$1m Dec 2017
Lowest value -$12m Dec 2009
Largest annual decline -$2m (-195.6%) Dec 2013 – Dec 2014

Capstone Therapeutics Corp
R&D Peer Comparison

Capstone Therapeutics Corp
Income Statement

USD
Metric FY2010 FY2011 FY2012 FY2013 FY2014 FY2015 FY2016 FY2017 FY2018 FY2019
0 0 0 0 0 0 0 0 0
— — — 0 — — — — — —
— — — 0 — — — — — —
(11.4m) (9.9m) (4.2m) (1.7m) (4.5m) (2.9m) (1.6m) (1.7m) (554k) (762k)
(3.2m) (3.5m) (1.8m) (641k) (1.5m) (1.8m) (543k) (641k) (554k) (762k)
R&D
(8.2m) (6.4m) (2.4m) (1m) (3.1m) (1.2m) (1m) (1m) — —
0 0 0 0 — — — — — —
(11.4m) (9.9m) (4.2m) (1.7m) (4.5m) (2.9m) (1.6m) (1.7m) (554k)
360k 30k 100k (111k) (43k) (24k) (81k) (111k) (248k) (261k)
0 0 0 0 — — — — — —
0 0 0 — — — — — — —
(11.1m) (9.9m) (4.1m) (1.8m) (4.6m) (3m) (1.7m) (1.8m) (802k) (1m)
180k 160k 0 19m 400k 192k 56k 19m 49k 24k
(10.9m) (9.7m) (4.1m) 17.2m (4.2m) (2.8m) (1.6m) 17.2m (753k) (999k)
— — 470k 0 0 0 946k 0 0 641k
(10.9m) (9.7m) (3.6m) (1.8m) (4.2m) (2.8m) (663k) (1.8m) (380k)
(7 992.64) (7 139.70) (2 632.35) (1 290.44) (3 063.97) (2 037.49) (487.50) (1 117.83) (209.94)

Capstone Therapeutics Corp
Glance View

Market Cap
1.3m USD
Industry
Biotechnology

Capstone Therapeutics Corp. is a biotechnology company. The company is headquartered in Tempe, Arizona. The firm is focused on development and commercialization of Apo E mimetic peptide AEM-28-14, through its investment in LipimetiX Development LLC. Apolipoprotein E is a 299 amino acid protein, which plays an important role in lipoprotein metabolism. AEM-28 is a 28 amino acid mimetic of Apo E and AEM-28-14, an analog of AEM-28, is a 28 amino acid mimetic of Apo E with an amino-hexanoic acid group and a phospholipid and both contain a domain, which anchors into a lipoprotein surface while also providing the Apo E receptor binding domain, which allows clearance through the heparan sulfate proteoglycan (HSPG) receptors in the liver. AEM-28-14 as an Apo E mimetic, has the potential to enhance the clearance of triglyceride- and cholesterol-rich lipoproteins from the plasma.

CAPS Intrinsic Value

Create a free account · No card needed

Back to Top